SHARE
COPY LINK

ZUG

Johnson and Johnson deny vaccine will be available privately in Switzerland

Johnson and Johnson have denied claims by Swiss public broadcaster SRF that the company's Janssen Vaccine would be available to private companies in Switzerland.

Johnson and Johnson deny vaccine will be available privately in Switzerland
Photo: AFP

The Covid-19 Vaccine Janssen, produced by American pharmaceutical company Johnson and Johnson, was approved by Swissmedic on Monday March 22nd.

However, as the government has declined to purchase the vaccine to incorporate it into its vaccine scheme, it is not expected to be publicly available.

On Tuesday, Switzerland’s public broadcaster SRF claimed the vaccine would however be available for private companies to vaccinate their employees.

Johnson and Johnson have denied this, saying their vaccine will not be made available to private entities. 

Here’s what you need to know.

Switzerland approves Johnson and Johnson – but will not purchase any doses

On Monday, the Swiss Agency for Therapeutic Products, Swissmedic, gave provisional approval for the vaccine manufactured by Johnson and Johnson (Covid-19 Vaccine Janssen).

This made it the third vaccine to be approved in Switzerland after the jabs from Moderna and Pfizer/BioNtech. Unfortunately however, this does not mean the vaccine will be available to the Swiss public anytime soon.

While Swissmedic has approved the vaccine for use in Switzerland, the Swiss government is yet to sign a vaccine supply contract with the manufacturer.

As The Local Switzerland reported yesterday, this is primarily because it would only be delivered in the summer “and that is too late for us”, said Nora Kronig, vice president of the Federal Office of Public Health (FOPH). 

READ MORE: Why Switzerland’s approval of the Johnson and Johnson jab will not speed up vaccinations

FOPH had previously announced the country aims to inoculate “everyone who wants it” by summer.

Kronig also said Switzerland is focusing on Pfizer / BioNtech and Moderna vaccines which use the so-called mRNA technology, “which is more effective, especially for vulnerable people”.

Johnson & Johnson vaccine uses a different technology.

Does this mean no Johnson and Johnson in Switzerland?

In a report on March 23rd Swiss public broadcaster SRF claimed any private entity wanting to import the vaccine can do so. 

“This means that a company in Switzerland, for example, can now buy this vaccine and have its staff vaccinated,” the media site claimed.

“At your own expense, but quickly and without any bureaucratic hurdles from the canton and federal government.”

However, ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­Thomas Moser, the Head of External Communications with Johnson and Johnson in Switzerland, told The Local Switzerland on Tuesday afternoon that the report was “incorrect” and as yet the vaccine would not be available to private entities. 

“In the current situation, J&J works exclusively with national and supranational authorities as well as international organisations such as COVAX to make our vaccine available,” he said, 

“This means that even with Swissmedic approval, direct orders will not be possible for the time being.”

As at Tuesday afternoon, the SRF report remained unchanged

Note: This article was changed on Tuesday afternoon to reflect the clarifications made by Johnson and Johnson directly to The Local Switzerland. 

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

COVID-19

Public Health Agency recommends two Covid doses next year for elderly

Sweden's Public Health Agency is recommending that those above the age of 80 should receive two doses of a Covid-19 vaccine a year, once in the spring and once in the autumn, as it shifts towards a longer-term strategy for the virus.

Public Health Agency recommends two Covid doses next year for elderly

In a new recommendation, the agency said that those living in elderly care centres, and those above the age of 80 should from March 1st receive two vaccinations a year, with a six month gap between doses. 

“Elderly people develop a somewhat worse immune defence after vaccination and immunity wanes faster than among young and healthy people,” the agency said. “That means that elderly people have a greater need of booster doses than younger ones. The Swedish Public Health Agency considers, based on the current knowledge, that it will be important even going into the future to have booster doses for the elderly and people in risk groups.” 

READ ALSO: 

People between the ages of 65 and 79 years old and young people with risk factors, such as obesity, diabetes, poor kidney function or high blood pressure, are recommended to take one additional dose per year.

The new vaccination recommendation, which will start to apply from March 1st next year, is only for 2023, Johanna Rubin, the investigator in the agency’s vaccination programme unit, explained. 

She said too much was still unclear about how long protection from vaccination lasted to institute a permanent programme.

“This recommendation applies to 2023. There is not really an abundance of data on how long protection lasts after a booster dose, of course, but this is what we can say for now,” she told the TT newswire. 

It was likely, however, that elderly people would end up being given an annual dose to protect them from any new variants, as has long been the case with influenza.

SHOW COMMENTS